Referring to the information published in Latvian media, which states that JSC Grindeks plans to move its manufacturing outside Latvia, we explain that the company’s management is examining various options to increase the manufacturing capacity. This includes starting up manufacturing in other countries or manufacturing expansion in existing Grindeks Group’s manufacturing units.
Decision has been already made on a new ampoule manufacturing line installation at Grindeks subsidiary HBM Pharma in Slovakia, thus increasing injection form medication manufacturing capacity up to 130 million ampoules per year.
Using its own financing, the Group is planning to invest at least 4 million euro in 2017.
Other decisions have not been adopted, as well as moving of manufacturing units operating in Latvia to other countries is not considered.